Cihan Cevik, MD
Interventional Cardiology · Colorado Springs, CONPI 1619169596
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (35.8%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Medtronic at 46.1% of the total.
Across 760 payments — averaging $84.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$30K
- Cardiovascular Systems Inc.$14K
- Abbott$7K
- Abiomed$5K
- Boston Scientific$3K
- Edwards Lifesciences$2K
- plus $4K from 11 others
Across 42 payments — averaging $824.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$35K
What the payments were for
- Consulting fees$3241%
- Speaking & faculty fees$19,42530%
- Travel & lodging$22,90036%
- Food & beverage$21,35033%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 451 | $29,526 |
| Cardiovascular Systems Inc. | 38 | $14,253 |
| Abbott | 116 | $6,708 |
| Abiomed | 45 | $5,341 |
| Boston Scientific | 26 | $2,599 |
| Edwards Lifesciences | 33 | $1,504 |
| W. L. Gore & Associates, Inc. | 20 | $1,168 |
| Penumbra, Inc. | 6 | $1,014 |
| Shockwave Medical, Inc | 8 | $728 |
| Asahi Intecc USA, Inc. | 9 | $645 |
| CSL Behring | 1 | $121 |
| Organogenesis Inc. | 1 | $120 |
| AstraZeneca | 1 | $112 |
| Acutus Medical, Inc. | 1 | $91 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Philips North America LLC | 1 | $21 |
| Terumo Medical Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$11,381
- Diamondback Coronary$10,794
- Impella$3,979
- ONYX FRONTIER$2,901
- RESOLUTE ONYX$1,878
- Diamondback Peripheral$1,677
- Coronary Orbital Atherectomy System$1,240
- XIENCE SIERRA$1,000
- Indigo System$984
- GENERAL VASCULAR ACCESS$870
- SYMPLICITY G3$818
- AVVIGO Guidance System$690
- TRICLIP$634
- Xience V coronary stent system$609
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$559
- AMPLATZER Occluders$518
- CARDIOFORM Septal Occluder$441
- HawkOne$376
- MitraClip$275
- Xience Sierra Coronary Stent$261
How this compares
$63,999 in reported general payments places this provider in the 85th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 79 | $106,176 |
| XareltoRivaroxaban | 38 | $54,906 |
| EntrestoSacubitril/Valsartan | 40 | $42,199 |
| Repatha SureclickEvolocumab | 36 | $40,180 |
| FarxigaDapagliflozin Propanediol | 14 | $19,141 |
| ClopidogrelClopidogrel Bisulfate | 684 | $8,017 |
| Atorvastatin Calcium | 304 | $3,363 |
| Metoprolol Succinate | 241 | $3,064 |
| Rosuvastatin Calcium | 108 | $1,960 |
| Cilostazol | 57 | $1,525 |
| Ranolazine ErRanolazine | 18 | $1,227 |
| Ezetimibe | 37 | $1,037 |
| Lisinopril | 114 | $830 |
| Amlodipine Besylate | 101 | $812 |
| Losartan Potassium | 101 | $791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $112 | $19,14114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 111 interventional cardiology providers in Colorado.
Other interventional cardiology in Colorado Springs
- Joseph LeeColorado Springs$15K
- Bishal BhandariColorado Springs$12K
- Harshal PatilColorado Springs$9K
- Christopher KovachColorado Springs$8K
- Ehrin ArmstrongEnglewood$718K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Srinivas IyengarBoulder$254K
- Nima AghiliLakewood$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.